Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00349778 · ClinicalTrials.gov registry record · Phase 2
High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT00349778: Completed Phase 2 study, sponsored by Stanford University.
NCT00349778 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 102 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00349778, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
This study uses a sequence of high-dose chemotherapy drugs and a stem cell transplant to treat multiple myeloma. The study is being performed to evaluate the efficacy and side effects of treatment. Specifically, the study is designed to reduce the risk of interstitial pneumonitis.
Interventions
- DRUG Cyclophosphamide
- DRUG Melphalan
- DRUG Etoposide
- DRUG Carmustine
- DRUG Filgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2006-08 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00349778
The ClinicalTrials.gov registry entry for NCT00349778 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00349778 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00349778 about?
NCT00349778 is a clinical study titled "High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma". This study uses a sequence of high-dose chemotherapy drugs and a stem cell transplant to treat multiple myeloma. The study is being performed to evaluate the efficacy and side effects of treatment. Specifically, the study is designed to reduce the risk of interstitial pneumonitis.
What is the current status of trial NCT00349778?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2006-08. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00349778?
The interventions under investigation include: Cyclophosphamide (DRUG), Melphalan (DRUG), Etoposide (DRUG), Carmustine (DRUG), Filgrastim (DRUG).
Who is sponsoring clinical trial NCT00349778?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.